MTOR and adenocarcinoma: In total, putative actionable genomic targets (FGFR2, BRAF-V600E, MTOR, NRAS, and KDM6A) were identified in 35% of the cases by OncoKB search, an important finding given the high number of fluent transitions from high-grade IEN to adenocarcinoma at the time of diagnosis (14/17 cases).